AMR within a wide range of infectious agents is a growing problem and threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi. AMR develops when microorganisms such as bacteria evolve to withstand the effects of the antimicrobial therapeutics that would have previously killed them or prevented their growth.

AMR is a serious global issue and requires urgent action. More than 2.8 million antibiotic-resistant infections occur annually in the United States alone, and more than 35,000 people die as a result.

CABP is an acute bacterial infection of the pulmonary parenchyma associated with chest pain, cough, sputum production, difficulty breathing, chills, rigors, fever, or hypotension, and is accompanied by the presence of a new lobar or multilobar infiltrate on a chest radiograph.

Streptococcus pneumoniae is a major cause of bacterial pneumonia and has developed resistance to clinically relevant antibiotics including macrolides, penicillins, and older generation tetracyclines.

ABSSSIs include cellulitis, erysipelas, wound infection, and major cutaneous abscess with a minimum lesion surface area of approximately 75cm². Common bacterial pathogens causing ABSSSI are Staphylococcus aureus including methicillin-resistant S. aureus (MRSA) and Streptococcus pyogenes.

Although several treatments are available, MRSA has developed resistance to many first-line antibiotics such as beta-lactams, macrolides, and fluoroquinolones.